Skip to main content
Journal cover image

The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.

Publication ,  Journal Article
Feinberg, D; Paul, B; Kang, Y
Published in: Cell Immunol
November 2019

A cure for multiple myeloma (MM), a malignancy of plasma cells, remains elusive. Nearly all myeloma patients will eventually relapse and develop resistance to currently available treatments. There is an unmet medical need to develop novel and effective therapies that can induce sustained responses. Early phase clinical trials using chimeric antigen receptor (CAR) T cell therapy have shown great promise in the treatment of relapsed and/or refractory MM. In this review article, we provide an overview of the CAR constructs, the gene transfer vector systems, and approaches for T cell activation and expansion. We then summarize the outcomes of several early phase clinical trials of CAR T cell therapy in MM and the novel CAR T targets that are under development. Finally, we explore the potential mechanisms that result in disease relapse after CAR T therapy and propose future directions in CAR T therapy in MM.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cell Immunol

DOI

EISSN

1090-2163

Publication Date

November 2019

Volume

345

Start / End Page

103964

Location

Netherlands

Related Subject Headings

  • T-Lymphocytes
  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell
  • Outcome Assessment, Health Care
  • Neoplasm Recurrence, Local
  • Multiple Myeloma
  • Immunotherapy, Adoptive
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Feinberg, D., Paul, B., & Kang, Y. (2019). The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cell Immunol, 345, 103964. https://doi.org/10.1016/j.cellimm.2019.103964
Feinberg, Daniel, Barry Paul, and Yubin Kang. “The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.Cell Immunol 345 (November 2019): 103964. https://doi.org/10.1016/j.cellimm.2019.103964.
Feinberg D, Paul B, Kang Y. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cell Immunol. 2019 Nov;345:103964.
Feinberg, Daniel, et al. “The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.Cell Immunol, vol. 345, Nov. 2019, p. 103964. Pubmed, doi:10.1016/j.cellimm.2019.103964.
Feinberg D, Paul B, Kang Y. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cell Immunol. 2019 Nov;345:103964.
Journal cover image

Published In

Cell Immunol

DOI

EISSN

1090-2163

Publication Date

November 2019

Volume

345

Start / End Page

103964

Location

Netherlands

Related Subject Headings

  • T-Lymphocytes
  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell
  • Outcome Assessment, Health Care
  • Neoplasm Recurrence, Local
  • Multiple Myeloma
  • Immunotherapy, Adoptive
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation